Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways

Cancer

Volumn 92, Issue 5, 2001, Pages 1130-1137

  Latil, Alain G ^a,b,g   Azzouzi, Rahmène ^c   Cancel, Géraldine S ^a   Guillaume, Emmanuelle C ^b   Cochan Priollet, Béatrix ^d   Berthon, Philippe L ^a,b   Cussenot, Olivier ^a,b,e,f  

^a Center for Research into Prostate Pathologies   (France)

^b Urogene SA   (France)

^c CHU NANCY BRABOIS   (France)

^d Lariboisière Laboratory of Anatomy and Pathology   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f University Institut of France (IUF)   (France)

^g Centre de Recherche pour les Pathologies Prostatiques (CeRePP UA3104 Paris VII)   (France)

Author keywords

Androgen biosynthesis; Cancer; Human prostate carcinoma; Metabolism pathways; Polymorphisms; Prostate carcinoma risk

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; CYTOCHROME P450; CYTOCHROME P450C17; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; ETHNOLOGY; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TANDEM REPEAT;

AGED; AGED, 80 AND OVER; ANDROGENS; AROMATASE; CHOLESTENONE 5 ALPHA-REDUCTASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; OXIDOREDUCTASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 0035446824     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010901)92:5<1130::AID-CNCR1430>3.0.CO;2-B     Document Type: Article

References (32)

1. Cancer Statistics 1997
2. Studies on prostatic cancer
3. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
4. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
5. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
6. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
7. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
8. CCAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
9. Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
10. Links between genetic and environmental factors and prostate cancer risk
11. Genetic variability of the human SDR5A2 gene: Implications for prostate cancer risk
12. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
13. A prevalent missense substitution that modulates activity of prostatic steroid 5 α-reductase
14. Tissue-specific cyclic adenosine 3′, 5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells
15. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
16. A rare CYP19 (aromatase) variant may increase the risk of breast cancer
17. Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer risk
18. The histology and prognosis of prostatic cancer
19. The TNM classification of prostate cancer
20. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
21. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer
22. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: A case-control analysis
23. Kinetic and biochemical characterization of naturally occuring variants of the steroid 5a-reductase type II (SDR5A2) gene
24. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer
25. Association of SRDA2 genotype and pathological characteristics of prostate tumors
26. CYP17 promotor polymorphism and ovarian cancer risk
27. A polymorphism in the CYP17 gene increases the risk of breast cancer
28. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer
29. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SDR5A2)
30. Prostate cancer associated with CYP17 genotype
31. A polymorphism in the CYP17 gene is associated with prostate cancer risk